| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/25/2013 | US20130101522 Ultrasound Contrast Agents And Process For The Preparation Thereof |
| 04/25/2013 | US20130101521 Methods devices and systems of preparing targeted microbubble shells |
| 04/25/2013 | US20130101516 Nanoparticles and nanoparticle compositions |
| 04/25/2013 | US20130099403 Semen cassiae soft capsule for reducing fat and losing weight and preparation method thereof |
| 04/25/2013 | US20130098797 Two phase pharmaceutical delivery system |
| 04/25/2013 | US20130098377 Excipients for nicotine-containing therapeutic compositions |
| 04/25/2013 | US20130098357 Cerivastatin to treat pulmonary disorders |
| 04/25/2013 | US20130097969 Process to improve stability of a pharmaceutical composition |
| 04/25/2013 | DE112011101605T5 Pharmazeutische Zusammensetzung umfassend Hydromorphon und Naloxon A pharmaceutical composition comprising hydromorphone and naloxone |
| 04/25/2013 | DE102011116824A1 Ingestion aiding medical products in the form of lollipops for infants comprises a drug for the alleviation of disease symptoms e.g. cold diseases, where the appropriate active ingredients is at the stem of the lollipop, |
| 04/25/2013 | CA2853084A1 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| 04/25/2013 | CA2852968A1 Pharmaceutical compositions of resveratrol |
| 04/25/2013 | CA2852917A1 Amine cationic lipids and uses thereof |
| 04/25/2013 | CA2852848A1 Acrylic polymer formulations |
| 04/25/2013 | CA2852788A1 Nicotine chewing gum with improved utilization of nicotine |
| 04/25/2013 | CA2852777A1 Lyophilized liposomes |
| 04/25/2013 | CA2852618A1 Pharmaceutical composition |
| 04/25/2013 | CA2852613A1 Paste comprising non-steroidal anti-inflammatory |
| 04/25/2013 | CA2852447A1 Two phase pharmaceutical delivery system |
| 04/25/2013 | CA2852417A1 Sustained-release preparation |
| 04/25/2013 | CA2852347A1 Pharmaceutical nanosuspension |
| 04/25/2013 | CA2851999A1 Solution for oral administration |
| 04/25/2013 | CA2851862A1 Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
| 04/25/2013 | CA2851425A1 Anti-tumoral compound and relative production process |
| 04/25/2013 | CA2851288A1 Stabilizers for hemostatic products |
| 04/25/2013 | CA2850521A1 Removable covering and interactive packaging |
| 04/24/2013 | EP2583968A1 Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses |
| 04/24/2013 | EP2583940A1 Stabilization of carbon nanomaterials and hydrophobic compounds by copolymers |
| 04/24/2013 | EP2583698A1 Absorbent polymeric compositions with varying counterion content and their methods of preparation and use |
| 04/24/2013 | EP2583691A1 Agent for treating renal fibrosis |
| 04/24/2013 | EP2583687A1 Use of botulinum toxin for treating hyperhydrosis |
| 04/24/2013 | EP2583681A1 Oral veterinary composition for salmonids, comprising 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide and use thereof for the treatment of infectious salmon anaemia (isa) in salmonids |
| 04/24/2013 | EP2583674A2 Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day |
| 04/24/2013 | EP2583673A1 Coating of cetyl myristate and/or cetyl palmitate particles |
| 04/24/2013 | EP2583672A1 Nanocrystals and amorphous nanoparticles and method for production of the same by a low energy process |
| 04/24/2013 | EP2583671A1 Colloidal nanoscale carriers for active hydrophilic substances and method for producing same |
| 04/24/2013 | EP2583670A1 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| 04/24/2013 | EP2583669A1 Taste-masked orally disintegrating tablets of memantine hydrochloride |
| 04/24/2013 | EP2583668A1 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| 04/24/2013 | EP2583662A1 Composition comprising a meroterpen to manage oily skin with tendency to develop acne |
| 04/24/2013 | EP2582812A1 Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
| 04/24/2013 | EP2582400A2 Tuned multifunctional magnetic nanoparticles for biomedicine |
| 04/24/2013 | EP2582393A1 Dose selection of adjuvanted synthetic nanocarriers |
| 04/24/2013 | EP2582387A2 Compositions and methods for treating inflammatory conditions |
| 04/24/2013 | EP2582386A2 Il-10 and methods of treating ocular and other diseases |
| 04/24/2013 | EP2582375A2 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| 04/24/2013 | EP2582367A2 Methods and systems for modulating hormones and related methods, agents and compositions |
| 04/24/2013 | EP2582365A1 Methods and compositions for stimulating reepithelialisation during wound healing |
| 04/24/2013 | EP2582364A2 Transdermal administration of memantine |
| 04/24/2013 | EP2582362A1 Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof |
| 04/24/2013 | EP2582361A2 Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| 04/24/2013 | EP2582360A2 Silk optical particles and uses thereof |
| 04/24/2013 | EP2582359A2 Solid compositions in form of powders or granulates for the oral administration of active ingredients and method for obtaining them |
| 04/24/2013 | EP2582358A1 Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
| 04/24/2013 | EP2582357A1 Transdermal absorption promoter, and external skin formulation thereof |
| 04/24/2013 | EP2582356A1 Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives |
| 04/24/2013 | EP2301524B1 Inhalable aztreonam without arginine for treatment and prevention of pulmonary bacterial infections |
| 04/24/2013 | CN202892459U Novel antineoplastic pills |
| 04/24/2013 | CN1953735B Oil-in-water emulsion for delivery |
| 04/24/2013 | CN1535141B Sustained-release composition and process for producing the same |
| 04/24/2013 | CN1462194B Oral preparations and supports for oral preparations |
| 04/24/2013 | CN103068944A Transdermal adhesive compositions, devices, and methods |
| 04/24/2013 | CN103068404A Pharmaceutical multimeric particles, and manufacturing method for same |
| 04/24/2013 | CN103068401A Method of treatment |
| 04/24/2013 | CN103068397A Concentrate for medical solutions, production thereof and use thereof in dialysis |
| 04/24/2013 | CN103068396A A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 04/24/2013 | CN103068395A Therapeutic agent for disease |
| 04/24/2013 | CN103068387A Compositions comprising buprenorphine |
| 04/24/2013 | CN103068382A Compounds and methods for skin repair |
| 04/24/2013 | CN103068377A Transdermal administration of memantine |
| 04/24/2013 | CN103068376A Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid |
| 04/24/2013 | CN103068375A Tablet sleeve for improved performance |
| 04/24/2013 | CN103068374A Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| 04/24/2013 | CN103068373A Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate |
| 04/24/2013 | CN103068372A Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| 04/24/2013 | CN103068371A Compositions and methods for improved retention of a pharmaceutical composition at a local administration site |
| 04/24/2013 | CN103068370A Compositions and methods for improved organ transplant preservation and acceptance |
| 04/24/2013 | CN103068369A Method for producing a lipid particle, the lipid particle itself and its use |
| 04/24/2013 | CN103068368A Method for producing a lipid particle, the lipid particle itself and its use |
| 04/24/2013 | CN103068367A Compositions and methods for stabilizing protein-containing formulations |
| 04/24/2013 | CN103068366A A liquid formulation of long-acting human growth hormone conjugate |
| 04/24/2013 | CN103068365A Removal of serine proteases by treatment with finely divided silicon dioxide |
| 04/24/2013 | CN103068364A Preservative free bimatoprost and timolol solutions |
| 04/24/2013 | CN103059297A Multifunctional degradable polyasparaginate modified polymer and preparation method thereof |
| 04/24/2013 | CN103059099A Novel pidotimod crystal form and preparation method thereof |
| 04/24/2013 | CN103058159A Hollow hierarchical hydroxyapatite microspheres and preparation method and application thereof |
| 04/24/2013 | CN103055343A Potato starch-hyaluronic acid composite hemostatic powder and preparation method thereof |
| 04/24/2013 | CN103055324A Compound of co-carried cis-platinum and adriamycin, micelle and preparation method of micelle |
| 04/24/2013 | CN103055322A Targeted sustained release medicine carrying nanoparticle and preparation method thereof |
| 04/24/2013 | CN103055320A Film coating material |
| 04/24/2013 | CN103055319A Medical slow-release film coating powder |
| 04/24/2013 | CN103055317A Instant plant soft capsule and preparation method thereof |
| 04/24/2013 | CN103055316A Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| 04/24/2013 | CN103055315A Single phase silicone acrylate formulation |
| 04/24/2013 | CN103055307A Injection composed of minocycline micro-capsule and lysozyme micro-capsule and used for treating periodontal disease |
| 04/24/2013 | CN103055305A A lyophilized preparation of a cytochrome C-containing pharmaceutical composition for injection and a preparation method thereof |
| 04/24/2013 | CN103055304A Compound temperature-sensitive gel for treating skin ulcer and preparation method thereof |
| 04/24/2013 | CN103055302A Ultrasonic biological effect mediated recombinant human endostatin controlled release preparation |
| 04/24/2013 | CN103055295A Chinese medicine for treating lumbar disc herniation and hyperosteogeny and use method of Chinese medicine |
| 04/24/2013 | CN103055294A Medicinal tablet for liver and gall excess fire clearing |